The most promising biomarkers so far are Nfs, specifically the combination of NfL and pNfH for the identification and determination of disease progression in ALS, as levels measured by ELISA are significantly higher than in other neurological diseases and ALS mimics. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.